Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer – ESMO-MCBS scores

Title
Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer – ESMO-MCBS scores
Authors
Keywords
-
Journal
CANCER TREATMENT REVIEWS
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2018-06-19
DOI
10.1016/j.ctrv.2018.06.008

Ask authors/readers for more resources

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now